American Journal of Cardiology
Volume 105, Issue 1 , Pages 105-111 , 1 January 2010

Prediction of Appropriate Defibrillator Therapy in Heart Failure Patients Treated With Cardiac Resynchronization Therapy

Received 8 July 2009 ,Revised 7 August 2009 ,Accepted 7 August 2009.

References 

  1. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26:1115–1140
  2. Fish JM, Brugada J, Antzelevitch C. Potential proarrhythmic effects of biventricular pacing. J Am Coll Cardiol. 2005;46:2340–2347
  3. Higgins SL, Hummel JD, Niazi IK, Giudici MC, Worley SJ, Saxon LA, et al. Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. J Am Coll Cardiol. 2003;42:1454–1459
  4. Zagrodzky JD, Ramaswamy K, Page RL, Joglar JA, Sheehan CJ, Smith ML, et al. Biventricular pacing decreases the inducibility of ventricular tachycardia in patients with ischemic cardiomyopathy. Am J Cardiol. 2001;87:1208–1210
  5. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the Cardiac Resynchronization-Heart Failure (CARE-HF) trial extension phase]. Eur Heart J. 2006;27:1928–1932
  6. Saxon LA, Bristow MR, Boehmer J, Krueger S, Kass DA, De Marco T, et al. Predictors of sudden cardiac death and appropriate shock in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial. Circulation. 2006;114:2766–2772
  7. Soliman OI, Theuns DA, Geleijnse ML, Anwar AM, Nemes A, Caliskan K, et al. Spectral pulsed-wave tissue Doppler imaging lateral-to-septal delay fails to predict clinical or echocardiographic outcome after cardiac resynchronization therapy. Europace. 2007;9:113–118
  8. Theuns DA, Thornton AS, Klootwijk AP, Scholten MF, Vantrimpont PJ, Balk AH, et al. Outcome in patients with an ICD incorporating cardiac resynchronisation therapy: differences between primary and secondary prophylaxis. Eur J Heart Fail. 2005;7:1027–1032
  9. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18:1440–1463
  10. Soliman OI, Theuns DA, ten Cate FJ, Nemes A, Caliskan K, Balk AH, et al. Predictors of cardiac events after cardiac resynchronization therapy with tissue Doppler-derived parameters. J Card Fail. 2007;13:805–811
  11. Soliman OI, Theuns DA, ten Cate FJ, Anwar AM, Nemes A, Vletter WB, et al. Baseline predictors of cardiac events after cardiac resynchronization therapy in patients with heart failure secondary to ischemic or nonischemic etiology. Am J Cardiol. 2007;100:464–469
  12. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114:e385–e484
  13. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140–2150
  14. Lam SK, Owen A. Combined resynchronisation and implantable defibrillator therapy in left ventricular dysfunction: Bayesian network meta-analysis of randomised controlled trials. BMJ. 2007;335:925
  15. Luu M, Stevenson WG, Stevenson LW, Baron K, Walden J. Diverse mechanisms of unexpected cardiac arrest in advanced heart failure. Circulation. 1989;80:1675–1680
  16. Soliman OI, Geleijnse ML, Theuns DA, Nemes A, Vletter WB, van Dalen BM, et al. Reverse of left ventricular volumetric and structural remodeling in heart failure patients treated with cardiac resynchronization therapy. Am J Cardiol. 2008;101:651–657
  17. Ypenburg C, van Erven L, Bleeker GB, Bax JJ, Bootsma M, Wijffels MC, et al. Benefit of combined resynchronization and defibrillator therapy in heart failure patients with and without ventricular arrhythmias. J Am Coll Cardiol. 2006;48:464–470
  18. Whang W, Mittleman MA, Rich DQ, Wang PJ, Ruskin JN, Tofler GH, et al. Heart failure and the risk of shocks in patients with implantable cardioverter defibrillators: results from the Triggers of Ventricular Arrhythmias (TOVA) study. Circulation. 2004;109:1386–1391
  19. Grimm W, Hoffmann JJ, Muller HH, Maisch B. Implantable defibrillator event rates in patients with idiopathic dilated cardiomyopathy, nonsustained ventricular tachycardia on Holter and a left ventricular ejection fraction below 30%. J Am Coll Cardiol. 2002;39:780–787
  20. De Maria R, Gavazzi A, Caroli A, Ometto R, Biagini A, Camerini F Italian Multicenter Cardiomyopathy Study (SPIC) Group. Ventricular arrhythmias in dilated cardiomyopathy as an independent prognostic hallmark. Am J Cardiol. 1992;69:1451–1457
  21. Doval HC, Nul DR, Grancelli HO, Varini SD, Soifer S, Corrado G, et al. Nonsustained ventricular tachycardia in severe heart failure (Independent marker of increased mortality due to sudden death). Circulation. 1996;94:3198–3203
  22. Tauke J, Goldstein S, Gheorghiade M. Digoxin for chronic heart failure: a review of the randomized controlled trials with special attention to the PROVED (Prospective Randomized Study of Ventricular Failure and the Efficacy of Digoxin) and RADIANCE (Randomized Assessment of Digoxin on Inhibitors of the Angiotensin Converting Enzyme) trials. Prog Cardiovasc Dis. 1994;37:49–58
  23. Lown B, Graboys TB, Podrid PJ, Cohen BH, Stockman MB, Gaughan CE. Effect of a digitalis drug on ventricular premature beats. N Engl J Med. 1977;296:301–306
  24. Beller GA, Conroy J, Smith TW. Ischemia-induced alterations in myocardial (Na+ + K+)-ATPase and cardiac glycoside binding. J Clin Invest. 1976;57:341–350
  25. Ho AT, Pai SM, Timothy P, Pai RG. Effect of concomitant antiarrhythmic therapy on survival in patients with implantable cardioverter defibrillators. Pacing Clin Electrophysiol. 2005;28:647–653
  26. Packer M, Gheorghiade M, Young JB, Costantini PJ, Adams KF, Cody RJ, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors (RADIANCE Study). N Engl J Med. 1993;329:1–7
  27. Gasparini M, Auricchio A, Regoli F, Fantoni C, Kawabata M, Galimberti P, et al. Four-year efficacy of cardiac resynchronization therapy on exercise tolerance and disease progression: the importance of performing atrioventricular junction ablation in patients with atrial fibrillation. J Am Coll Cardiol. 2006;48:734–743
  28. Bocker D, Bansch D, Heinecke A, Weber M, Brunn J, Hammel D, et al. Potential benefit from implantable cardioverter-defibrillator therapy in patients with and without heart failure. Circulation. 1998;98:1636–1643
  29. Leor J, Goldbourt U, Rabinowitz B, Reicher-Reiss H, Boyko V, Kaplinsky E, et al. Digoxin and increased mortality among patients recovering from acute myocardial infarction: importance of digoxin dose. Cardiovasc Drugs Ther. 1995;9:723–729
  30. Abraham WT, Young JB, Leon AR, Adler S, Bank AJ, Hall SA, et al. Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure. Circulation. 2004;110:2864–2868

PII: S0002-9149(09)02224-3

doi: 10.1016/j.amjcard.2009.08.659

American Journal of Cardiology
Volume 105, Issue 1 , Pages 105-111 , 1 January 2010

Article Tools

* Image Usage & Resolution